Day: October 20, 2025
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-doseCompared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p
2025 Q3 Sales: Revenue of €6.1 Billion, Stable on an Organic Basis. Strong Financial Discipline. 2025 Guidance Confirmed
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
NANTERRE (FRANCE) OCTOBER 20, 2025
THIRD-QUARTER 2025 SALES
REVENUE OF €6.1 BILLION, STABLE ON AN ORGANIC BASIS
STRONG FINANCIAL DISCIPLINE
2025 GUIDANCE CONFIRMEDSTABLE ORGANIC SALESReported sales down 3.7% due to a negative currency impact of €238m (-3.7%),
Organic growth of 1.1% in product sales
Solid growth in Electronics, Clean Mobility and Lifecycle Solutions
China activity reflecting an unfavorable mix between Chinese customersSUSTAINED PROGRESS OF EFFICIENCY MEASURESEU-FORWARD European competitiveness plan at full-speed
Launch of the global SIMPLIFY program to reduce indirect and structural costs
Maximum flexibility in production cost managementSIGNIFICANT IMPROVEMENT IN DEBT PROFILE2026 maturities nearly repaid, with a balanced maturity profile from 2027 onwardCONFIRMED FULL-YEAR 2025 GUIDANCESales, operating...
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Written by Customer Service on . Posted in Public Companies.
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1
IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer
Data being presented as part of the Presidential Symposium at the ESMO Congress 2025Basel, 20 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for people with muscle-invasive bladder cancer (MIBC) who are at risk of recurrence after surgery (cystectomy) and have detectable circulating tumour DNA (ctDNA). In this ctDNA-guided setting, Tecentriq reduced the risk of death (overall survival, OS) by 41% and the risk of disease recurrence...
